New peptide antagonists at glutamate and nmda receptors

Details New peptide antagonists at glutamate and nmda receptors New peptide antagonists at glutamate and nmda receptors

A - Human Necessities

61

K

A61K 38/30 (2006.01) A61K 38/06 (2006.01) A61K 38/09 (2006.01) A61K 38/25 (2006.01) A61K 38/28 (2006.01)

Patent

CA 2162924

The invention relates to the use of peptide antagonists at NMDA receptors for the manufacture of a medicament to influence the function of NMDA-receptor-controlled cells, such as neurons or glial cells in the central nervous system. The medicament comprises normally glutamic acid-terminating peptides chosen among (1-5)GnRH, (1-3)IGF- I, (1-37)GRF and C-peptide of insulin. The medicament could be used for the treatment of acute or chronic disorders of the central nervous system and the treatment of hypoxic, ischemic and metabolic brain disorders such as stroke and hypoglycemia, traumatic or inflammatory injuries to the brain or traumatic head injuries. It also relates to a method for treatment.

Affiliated with

Also associated with

Rating

New peptide antagonists at glutamate and nmda receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with New peptide antagonists at glutamate and nmda receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and New peptide antagonists at glutamate and nmda receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2007130